SCHEMBL3375280

SCHEMBL3375280

OC1C[N]1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL358718 0.70
SCHEMBL188255 0.63
SCHEMBL3857199 0.60
SCHEMBL5160419 0.60
SCHEMBL5160421 0.60
SCHEMBL6391227 0.60
SCHEMBL414574 0.60
SCHEMBL2481760 0.58
SCHEMBL5567184 0.58
SCHEMBL450125 0.50

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240166617-A1 PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF GEODE THERAPEUTICS INC (US) 2024-05-23 US disclosed
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-04-18 US disclosed
WO-2024059237-A2 NOVEL GLUCOCORTICOID RECEPTOR AGONISTS AND IMMUNOCONJUGATES THEREOF ADCENTRX THERAPEUTICS INC. (US) 2024-03-21 WO disclosed
WO-2024059236-A1 NOVEL CAMPTOTHECIN ANALOGS AND IMMUNOCONJUGATES THEREOF ADCENTRX THERAPEUTICS INC. (US) 2024-03-21 WO disclosed
CN-117615763-A Phosphoinositide 3 kinase beta inhibitor, composition and preparation method thereof 健道生物医药有限公司 2024-02-27 CN disclosed
WO-2024026129-A2 TRICYCLIC ARYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF ENSEM THERAPEUTICS, INC. (US) 2024-02-01 WO disclosed
WO-2024026128-A2 TRICYCLIC ARYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF ENSEM THERAPEUTICS, INC. (US) 2024-02-01 WO disclosed
WO-2023244713-A1 QUINAZOLINE DERIVATIVES, COMPOSITIONS AND METHODS THEREOF ENSEM THERAPEUTICS, INC. (US) 2023-12-21 WO disclosed
WO-2023244710-A1 ANILINO-PYRAZOLE DERIVATIVES, COMPOSITIONS AND METHODS THEREOF ENSEM THERAPEUTICS, INC. (US) 2023-12-21 WO disclosed
EP-4284375-A1 PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF Geode Therapeutics Inc. (US) 2023-12-06 EP disclosed
WO-2004014868-A2 PYRIMIDINE-2,4-DIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed
US-20040034009-A1 1,6-Fused uracil derivatives as matrix metalloproteinase inhibitors ROARK WILLIAM HOWARD (US) 2004-02-19 US disclosed
WO-2004014384-A2 CYCLIC COMPOUNDS CONTAINING ZINC BINDING GROUPS AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed
WO-2004014921-A1 5,6-FUSED URACIL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed
WO-2004014354-A1 1,6-FUSED URACIL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed
EP-1272198-A1 USE OF ORGANOPHOSPHOROUS COMPOUNDS FOR PRODUCING A MEDICAMENT FOR TREATING INFECTIONS Jomaa Pharmaka GmbH (DE) 2003-01-08 EP disclosed
WO-2002078714-A1 FORMULATIONS WHICH ARE RESISTANT TO GASTRIC JUICE AND ARE USED TO APPLY ANTI-INFECTIVE COMPOUNDS INHIBITING THE 2-C-METHYLERYTHROSE-4 METABOLIC PATHWAY, AND THE SALTS AND ESTERS OF THE SAME JOMAA PHARMAKA GMBH (DE) 2002-10-10 WO disclosed
WO-2001070237-A1 USE OF ORGANOPHOSPHOROUS COMPOUNDS FOR PRODUCING A MEDICAMENT FOR TREATING INFECTIONS JOMAA PHARMAKA GMBH (DE) 2001-09-27 WO disclosed
EP-1100510-A2 COMBINED PREPARATION OF ANTI-INFECTIOUSLY ACTIVE COMPOUNDS WHICH INHIBIT THE 2-C-METHYLERYTHROSE-4 METABOLIC PATHWAY, AND INHIBITORS OF LIPID METABOLISM Jomaa, Hassan (DE) 2001-05-23 EP disclosed
WO-1999066875-A2 COMBINED PREPARATION OF ANTI-INFECTIOUSLY ACTIVE COMPOUNDS WHICH INHIBIT THE 2-C-METHYLERYTHROSE-4 METABOLIC PATHWAY, AND INHIBITORS OF LIPID METABOLISM JOMAA HASSAN (DE) 1999-12-29 WO disclosed